USPTO Patent Grants - Peptides (C07K)

Daesang Corporation L-Glutamic Acid Producing Corynebacterium Mutant Patent

The USPTO granted Patent US12600939B2 to Daesang Corporation on April 14, 2026, covering a mutant Corynebacterium glutamicum strain with enhanced L-glutamic acid productivity. The mutant strain incorporates a mechanosensitive ion channel gene derived from Corynebacterium sp., improving glutamic acid release and yield. The patent includes 3 claims and names Young Ju Lee, Bong Ki Kim, Min Jin Choi, Seok Hyun Park, and Jae Chun Han as inventors.

Method for Purifying Membrane Protein Complex - Sumitomo Patent US12606807B2

USPTO granted Patent US12606807B2 to Sumitomo Rubber Industries, Ltd. on April 21, 2026. The patent covers a method for purifying proteins derived from membrane protein complexes using synthetic polymers, antibodies, and pH-controlled elution with solvent extraction. The patent has 15 claims with a filing date of March 23, 2022.

US12606640B2 - Recombinant Antimicrobial Polypeptide

The USPTO granted US Patent US12606640B2 to IRTA, Institut de Recerca i Transferència Agroalimentàries, covering a recombinant antimicrobial multidomain polypeptide comprising at least three peptidic domains — a non-enzymatic antimicrobial domain, a bacterial binding domain, and an enzymatic antimicrobial domain. The patent contains 21 claims and was filed on February 18, 2020.

Inhibitory T Cell Receptor Peptides and Discovery Methods

USPTO granted patent US12606816B2 to Janux Therapeutics, Inc. covering inhibitory T cell receptor peptides and methods of inhibiting T cell receptor interactions with peptide-major histocompatibility complexes. The patent discloses peptides that bind to T cell receptors without requiring major histocompatibility complex assistance. Six claims are associated with this patent.

Fish Totivirus Patent Granted to Pharmaq AS

The USPTO granted Patent US12606875B2 to Pharmaq AS on April 21, 2026, covering a novel fish Totivirus that causes mortality in fish and methods for detecting the virus. The patent names inventors Stian Nylund, Liv Sandlund, and Arnfinn L. Okland. The filing date was February 4, 2020, under Application No. 17433416, with 22 claims registered.

CD25 Chimeric Antigen Receptor Patent Granted to Montefiore Medical Center

USPTO granted US Patent US12606630B2 to Montefiore Medical Center covering CD25 chimeric antigen receptors and their therapeutic uses. The patent, applied for in August 2020, contains 19 claims covering compositions and methods for immune enhancement and cancer treatment. This grant confers exclusive intellectual property rights to the assignee for the claimed biological compositions and treatment methods.

DLL3 Targeting CAR-T Cell Therapy Patent Granted to Allogene Therapeutics

The USPTO granted Patent US12606623B2 to Allogene Therapeutics, Inc. covering DLL3 binding agents and chimeric antigen receptors (CARs) for use in immune cell therapies, specifically CAR-T cells. The patent includes 26 claims and covers methods of making and using DLL3-specific CARs. This grant establishes exclusive IP rights for the assignee in the specified therapeutic domain.

Surrozen Operating Inc. Secures Anti-Frizzled Antibody Patent

The USPTO granted Patent US12606629B2 to Surrozen Operating, Inc. on April 21, 2026. The patent covers monospecific anti-Frizzled monoclonal antibodies and related compositions for therapeutic applications. The application, filed July 2, 2020, received 10 claims under CPC classifications including C07K 16/2863.

Anti-CD40 Antibodies and Methods of Use (Apexigen Patent Grant)

USPTO granted US Patent 12,606,632 B2 to Apexigen, Inc. on April 21, 2026. The patent covers high affinity anti-CD40 monoclonal antibodies and related compositions for therapeutic use in cancer and other diseases. Named inventors are Yongke Zhang, Guo-Liang Yu, and Weimin Zhu.

US12606631B2 - ETAR Antibodies, Patent Grant

USPTO granted Patent US12606631B2 to REMD Biotherapeutics Inc for isolated antibodies that specifically bind endothelin A receptor (ETAR). The antibodies have high affinity for ETAR, block ET-1 binding to ETAR, exhibit reduced immunogenicity, and have longer serum half-life compared to small molecule ETAR antagonists. Seven claims were allowed.

NovoMab BioPharmaceuticals Inc CTLA-4 Antibody Patent US12606624B2

The USPTO granted Patent US12606624B2 to NovoMab BioPharmaceuticals Inc covering an antibody that specifically binds to human CTLA-4. The patent discloses three complementarity-determining regions (CDR1-3) and applications in medicaments and kits for potential tumor growth inhibition. The patent application (18456503) was filed on August 27, 2023.

Shanghai Henlius Biotech Anti-CD73 Antibody Patent US12606633B2

The USPTO granted Patent US12606633B2 to Shanghai Henlius Biotech, Inc. on April 21, 2026, covering anti-CD73 antibodies, variants, and antigen binding fragments that bind human CD73 with high affinity and suppress enzymatic activity. The patent includes 17 claims and covers isolated nucleic acid molecules, expression vectors, host cells, and related pharmaceutical compositions for treating subjects.

Nanjing Legend Biotech CAR-T Patent, GPC2 Cancer Immunotherapy

The USPTO granted Patent US12606635B2 to Nanjing Legend Biotech Co., Ltd. covering GPC2-specific antibodies, antigen binding fragments, and chimeric antigen receptor (CAR) constructs for cancer immunotherapy. The patent encompasses T cells engineered with the disclosed CAR constructs. The application (No. 17910608) was filed March 12, 2021, and contains 19 claims.

Technion Patents Heparanase-Neutralizing A54 mAb

The USPTO granted patent US12606637B2 to Technion Research & Development Foundation Limited on April 21, 2026. The patent covers heparanase-neutralizing monoclonal antibody A54 (IgG-1 mAb), its epitope HBD-II, pharmaceutical compositions, and uses for treating cancer, inflammation, viral infections, diabetes, and related complications. The patent also discloses combinatorial cancer therapies combining the A54 mAb with chemotherapy or radiation.

Netherton Syndrome LEKTI Microbe Patent - Azitra Inc

The USPTO granted US Patent 12606610B2 to Azitra Inc covering engineered microbes expressing recombinant LEKTI domains for the treatment of Netherton Syndrome. The patent contains 15 claims spanning compositions, methods, and kits. Inventors are Travis Michael Whitfill and Azim Momin Munivar.

Recombinant CCN Domain Proteins and Fusion Proteins

USPTO granted Patent US12606602B2 to Oslo University Hospital HF covering recombinant proteins having CCN family thrombospondin type 1 repeat homology domains and fusion proteins combined with fusion partners and linker regions. The patent contains 18 claims and includes novel protease resistant Fc-fragments with applications in oncology.

Nucleic Acid Construct Encoding Chimeric Rhodopsin - Restore Vision

USPTO granted Patent US12606606B2 to Restore Vision Inc. for a nucleic acid construct encoding a chimeric rhodopsin protein combining ion-transporting receptor rhodopsin with G protein-coupled receptor rhodopsin sequences. The patent contains 17 claims classified under C07K peptide chemistry and covers applications for preventing retinal diseases and enhancing visual function.

Petrobras Granted Patent for Genetically Modified Microorganisms Producing Surfactant Proteins

The USPTO granted Patent US12606601B2 to Petróleo Brasileiro S.A.—Petrobras on April 21, 2026, covering genetically modified microorganisms that heterologously produce modified versions of the surfactant protein Lv-ranaspumin-1 (Lv-Rsn-1), originally derived from the Northeastern Pepper Frog. The patent also claims the synthetic genes, expression cassettes, expression vectors, and specific transgenic bacteria and yeast strains. The surfactant protein has demonstrated properties including surfactancy, emulsification, and dispersancy, enabling industrial applications without natural extraction from frog nest foam.

Polypeptides Mimicking SP-C/SP-B Surfactant for RDS Treatment

The USPTO has granted Patent US12606609B2 to CHIESI FARMACEUTICI S.p.A. covering polypeptides that mimic the properties of human lung surfactant proteins SP-C and SP-B. The invention includes corresponding reconstituted surfactants and pharmaceutical compositions for treating or preventing neonatal respiratory distress syndrome (RDS) or acute RDS. The patent contains 30 claims and names Tore Curstedt and Jan Johansson as inventors.

IgE Antibody Composition for Cancer Treatment, King's College

USPTO granted Patent US12606617B2 to King's College London on April 21, 2026. The patent covers a pharmaceutical unit dosage composition comprising an IgE antibody in a dosage of less than 50 mg, intended for administration to mammalian subjects for treating cancer, specifically human ovarian cancers. The patent names four inventors and contains 21 claims.

LG Chem Anti-LILRB1 Antibody Patent US12606620B2

The USPTO granted Patent US12606620B2 to LG CHEM, LTD. on April 21, 2026, covering an anti-LILRB1 antibody with increased specificity and its uses in treating cancer. The patent includes 17 claims and covers the antibody or antigen-binding fragments thereof.

DANISCO US Inc. Modified Yeast Over-Expressing GDS1 for Ethanol Production

The USPTO granted patent US12606599B2 to DANISCO US Inc. on April 21, 2026, covering modified yeast strains that over-express the glycerol-deficient suppressor GDS1. The patented yeast produces increased ethanol and decreased acetate compared to parental cells, making it suitable for large-scale ethanol production from starch substrates where acetate is undesirable. The patent names Zhongqiang Chen, Min Qi, Luan Tao, and Quinn Qun Zhu as inventors and covers compositions and methods for industrial fermentation applications.

DENV4 NS1 Antibody Patent US12606611B2 Granted to US Dept Health

The USPTO granted Patent No. US12606611B2 to the United States of America, as represented by the Secretary of the Department of Health & Human Services, covering antibodies that specifically bind to Dengue virus serotype 4 (DENV4) non-structural protein 1 (NS1). The patent includes 16 claims and names Elizabeth Anne Hunsperger and Tesfaye Gelanew Taye as inventors.

Anti-TIGIT Antibodies Treat Cancers, Viral Infections

USPTO granted patent US12606619B2 to Huahui Health Ltd. on April 21, 2026. The patent covers human monoclonal antibodies targeting TIGIT (T-cell immunoreceptor with Ig and ITIM domains) and their use in treating immune-related diseases including cancers and viral infections. Inventors: Jianhua Sui, Fang Yang, Linlin Zhao, Zhizhong Wei. The application includes 21 claims.

Chimeric Klebicins - Bactoclear Holdings

The USPTO granted US Patent 12,606,598B2 to Bactoclear Holdings PTE, Ltd. covering chimeric klebicins — engineered antimicrobial proteins combining translocation, receptor-binding, and bactericidal domains from different klebicin sources. The patent includes 15 claims and covers compositions, kits, and methods of use designed to improve target cell range and bactericidal activity against bacterial pathogens.

Evaxion Biotech Pseudomonas Aeruginosa Vaccine Patent

The USPTO granted patent US12606597B2 to Evaxion Biotech A/S on April 21, 2026. The patent covers immunogenic proteins from Pseudomonas aeruginosa as well as nucleic acids, vectors, and transformed cells useful for expression of the proteins, along with methods for prophylaxis of infection. The patent contains 12 claims.

Macrocyclic Compounds, SRC MET Inhibitor, Cancer Treatment

USPTO granted patent US12606571B2 to Turning Point Therapeutics, Inc. for macrocyclic compounds that inhibit SRC and MET and/or CSF1R, pharmaceutical compositions thereof, and methods of using such compounds to treat cancer. The patent contains 9 claims and was granted on April 21, 2026.

Recombinant AAV Vectors for Treating Parkinson's, MSA, Gaucher's Disease - US12605467B2

USPTO granted patent US12605467B2 to Shanghai Vitalgen Biopharma Co., Ltd. on April 21, 2026, covering recombinant adeno-associated viral (rAAV) vectors encoding aromatic L-amino acid decarboxylase (AADC), glucocerebrosidase (GBA1), and neurotrophic factors (CDNF or GDNF) for treating neurodegenerative disorders including Parkinson's disease, multiple system atrophy, and Gaucher's disease. The patent contains 14 claims and names three inventors.

High-activity Blood Coagulation Factor XI Mutant Ala570Thr Patent

The USPTO granted patent US12605430B2 to Ruijin Hospital Shanghai Jiaotong University School of Medicine for a high-activity blood coagulation factor XI mutant (Ala570Thr/A570T). The mutant demonstrates resistance to physiological inhibitors after activation and exhibits strong blood coagulation activity. The patent covers nucleotide sequences (SEQ ID NOs: 1-4), amino acid sequence (SEQ ID NO: 5), and applications for treating hemorrhagic diseases through gene therapy, gene editing, and recombinant protein replacement treatments.

Mitochondria-enriched Genetically Engineered Cells and Uses Thereof

The USPTO granted Patent No. US12605410B2 to Minovia Therapeutics Ltd. covering pharmaceutical compositions of mitochondrially-enriched genetically engineered T cells and methods of using such cells to treat diseases and disorders. The patent, with 18 claims, was filed on March 30, 2021. This IP grant gives Minovia enforceable rights to its cell engineering technology through the patent term.

PSMA-Targeted Cancer Immunotherapy Patent Granted to Methodist Hospital

The USPTO granted patent US12605446B2 to The Methodist Hospital covering engineered cells with chimeric antigen receptors (CARs) targeting PSMA for prostate cancer treatment. The patent, filed August 20, 2021, contains 15 claims and names Bin He as inventor. This grant confers exclusive IP rights for PSMA-targeted CAR-T immunotherapies in the United States.

Immunogenic Trimers - International AIDS Vaccine Initiative

The USPTO granted Patent US12605441B2 to International AIDS Vaccine Initiative, Inc. on April 21, 2026. The patent covers immunogenic trimer compositions including PGT121-germline-targeting designs, trimer stabilization designs, and trimer nanoparticle configurations for use in immunization regimens against HIV.

Peptide Inhibitors for SARS-CoV-2 Methyltransferase

The USPTO granted Patent US12605423B2 to United Arab Emirates University for synthetic peptide inhibitors designed to inhibit SARS-CoV-2 replication through targeting of Methyltransferase complexes (NSP10/NSP16 and NSP10/NSP14) for COVID-19 treatment. The patent covers Peptide P3, a synthetic analog of amino acids 89-96 of the SARS-CoV-2 non-structural protein 10 (NSP10), modified to enhance cell membrane penetration.

CSF-1R Kinase Inhibitor Patent Grant

USPTO granted patent US12605375B2 to Shanghai Runshi Medical Technology Co., Ltd. covering the use of a CSF-1R kinase inhibitor compound for treating diseases related to CSF-1R kinase signal transduction and for regulating immunization. The patent claims 8 total claims. The compound demonstrated superior inhibition of CSF-1R kinase activity and anti-tumor efficacy compared to marketed drug Pexidartinib in preclinical studies.

TNF Muteins and Uses Thereof

USPTO granted Patent US12605425B2 to Oxford University Innovation Limited for tumour necrosis factor (TNF) muteins that function as selective agonists of tumour necrosis factor receptor 1 (TNFR1). The patent covers compositions comprising these TNF muteins, methods of treating or detecting tumours, and related nucleic acids and host cells. This is a routine patent grant conferring exclusive rights to the assignee with no immediate compliance obligations for other parties.

CP2c-Targeting Peptide Anticancer Agent Patent Grant

USPTO granted patent US12605453B2 to Industry-University Cooperation Foundation Hanyang University on April 21, 2026, covering a CP2c-targeting peptide-based anticancer agent. The peptide binds to transcription factor CP2c to inhibit the formation of CP2c homotetramers and CP2c/CP2b/PIAS1 heterohexamers, inducing cancer cell-specific cell death. A fatty acid is bound to the peptide for in vivo stability. The patent contains 5 claims.

Tetrapeptide Compositions for Treating Eye Disorders

The USPTO granted patent US12605422B2 to S.I.S SHULOV INNOVATIVE SCIENCE LTD. on April 21, 2026, covering tetrapeptide pharmaceutical compositions for treating degenerative, age-related, and trauma-induced disorders of the eye. The patent, application number 17762984, was filed September 23, 2020, and contains 20 claims classified under CPC codes A61K 38/07, A61P 25/28, and C07K 5/1024.

Engineered Probiotics for Treatment and Immunity Against Viruses

The USPTO granted Patent US12605413B2 to the University of Cincinnati covering an engineered probiotic bacterium comprising heterologous nucleic acid encoding an anti-spike glycoprotein nanobody of a coronavirus. In one embodiment, the bacterium is Escherichia coli Nissle 1917 with the nanobody appearing on the bacterial surface. The patent contains 9 claims and was filed on April 19, 2021.

Carbohydrate Binding Module Variants and Hybrid Polypeptides Comprising Same

USPTO granted Patent US12600996B2 to Novozymes A/S on April 14, 2026, covering cellobiohydrolase variants and carbohydrate binding module variants. The patent also protects polynucleotides encoding the variants, nucleic acid constructs, vectors, host cells, and associated production methods. The patent contains 33 claims and was filed under application number 17812259.

ELTA Patent - Enzymatic ADP-ribose Labeling Methods

USPTO granted patent US12601734B2 to Johns Hopkins University covering ELTA (Enzymatic Labeling of Terminal ADP-ribose) technology for labeling free, protein-conjugated, or nucleic acid-conjugated ADP-ribose molecules at their 2'-OH termini. The patent contains 28 claims and covers applications including fluorescence-based biophysical measurement of PAR-protein interaction, detection of PAR length from cells, and enrichment of ADP-ribosylated peptides for mass spectrometry identification.

Fusion Protein Enzyme for Biocatalytic Reduction of Cystine to Cysteine

USPTO granted patent US12600995B2 to Wacker Chemie AG for a fusion protein enzyme combining thioredoxin and thioredoxin reductase activities from E. coli to catalyze the reduction of cystine to cysteine. The patent contains 7 claims and was assigned CPC classifications related to biochemistry and peptide chemistry.

Beta Ketoacyl Synthase IV Variants by CORBION BIOTECH

USPTO granted Patent US12600994B2 to CORBION BIOTECH, INC. covering non-natural variant β-ketoacyl-ACP synthase (KAS) IVa enzymes, polynucleotides encoding such variants, host cells expressing such variants, and oils and oil products produced by such cells. The patent names Joshua Ferreira, Janice Lau Wee, and Nien-Hsi Ko as inventors. Filing date was January 15, 2021, with 21 claims granted.

US12600990B2 - mRNA Induced Expression of BMP and Receptor and Methods Related Thereto

USPTO granted patent US12600990B2 to inventors Alexander Day and Bradford Mullin covering methods of preparing synthetic mRNA encoding bone morphogenic protein (BMP) and/or BMP receptor in lipid-solubilized carriers for intraoperative delivery to bone fusion beds. The patent includes 20 claims and covers CPC classifications including C12N 15/88, A61K 47/543, A61K 48/0041, and C07K 14/51.

AB Enzymes Xylanase Variants - Patent US12600960B2

The USPTO granted Patent US12600960B2 to AB Enzymes Finland Oy for xylanase variant polypeptides comprising amino acid sequences with at least 79% but less than 100% identity to SEQ ID NO: 1, featuring at least one disulfide bridge and amino acid substitutions at positions 23 and/or 28. The patent covers the variant polypeptide, fusion proteins, enzyme compositions, recombinant host cells for production, and methods of use.

Method for Preparing Hemogenic Endothelium Cell and Hematopoietic Stem Cell

USPTO granted Patent US12600954B2 to Allife Medicine (Beijing) Limited on April 14, 2026, covering methods for preparing hematopoietic endothelial cells and hematopoietic stem cells or hematopoietic stem and progenitor cells. The methods use transcription factors LCOR, HOXA9, HOXA5, RUNX1, and ERG during induced pluripotent stem cell differentiation. The patent application was filed March 19, 2025, and contains 11 claims.

Method of Determining or Influencing Chondrogenic Potential of Mesenchymal Stromal Cells

USPTO granted Patent US12600952B2 to AO TECHNOLOGY AG on April 14, 2026. The patent covers methods of increasing chondrogenic potential of mesenchymal stromal cells (MSCs) by manipulating TGFβR1, TGFβR2, and ACVRL1 expression levels. The patent contains 23 claims and has 5 CPC classifications spanning cell therapy and peptide technologies.

Multiplex Genome Editing of Immune Cells for Enhanced Functionality and Resistance to Suppressive Environment

The USPTO granted patent US12600944B2 to the Board of Regents, The University of Texas System covering methods for multiplex genome editing of immune cells, including disruption of multiple genes and insertion of chimeric antigen receptors at specific gene loci. The patent names Rafet Basar, Elizabeth Shpall, and Katy Rezvani as inventors and contains 14 claims. The filing date was November 27, 2019.

Antibody for Binding to Interleukin 4 Receptor

USPTO granted Patent US12600771B2 to Connect Biopharma Hong Kong Limited for an antibody capable of binding to the interleukin 4 (IL-4) receptor. The patent covers the antibody itself, encoding nucleic acids, vectors, host cells, production methods, medical uses, and kits. The patent contains 30 claims and was filed on November 15, 2023.

CAR T Cell Therapy Patent - US12600775B2

USPTO granted Patent US12600775B2 to Kite Pharma, Inc. for methods of preparing, producing, processing, culturing, isolating, or making cells suitable for immune or cell therapy and their use in cell therapy. The patent covers CAR T cell therapy methods with applications in cancer treatment.

Chimeric Antigen Receptors Targeting CD79B and CD19 for Cancer Treatment

USPTO granted Patent US12600760B2 to The General Hospital Corporation on April 14, 2026, covering chimeric antigen receptors (CARs) targeting CD79B and CD19 for cancer treatment. The patent includes methods for producing T cells with CARs having extracellular domains that bind both CD79b and CD19. Invented by Marcela V. Maus, the patent covers upfront treatment methods where the patient has not been previously treated for the cancer.